Q-omics provides the consensus-scored MIR4664 profile across patient tissues and cancer cell-line models. MIR4664 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4664 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MIR4664 RNA expression shows 18,928 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where MIR4664 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4664 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4664 survival associations across molecular data types. MIR4664 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4664 RNA expression–survival associations across cancer types. High MIR4664 expression shows unfavorable associations in CESC, UVM, SKCM and LUSC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4664 RNA expression.
This table summarizes MIR4664 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4664. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4664 shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD, LIHC, BLCA and HNSC. The COAD box plot shows higher MIR4664 RNA expression in tumor versus normal tissue (log2 FC = +1.958, t-test p < 0.001).
This table shows molecular features associated with MIR4664 in patient tissues and cancer cell lines. In patient samples, MIR4664 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
